Drug intelligence / Profile preview

Er Long Pian

Development stage: Unknown
Lead developer: Shaanxi Tianyang Pharmaceutical
Administration: Oral

Overview

Er Long Pian is a traditional Chinese medicine (TCM) formulation developed and manufactured by Shaanxi Tianyang Pharmaceutical. It is an approved pharmaceutical product in China, primarily indicated for the treatment of hearing loss, sudden deafness, and tinnitus. According to TCM theory, the formula is designed to clear liver and gallbladder fire and sedate the liver, addressing the underlying internal heat that is believed to cause auditory disturbances. The preparation typically consists of a complex mixture of herbal and mineral ingredients, including Gentianae Radix et Rhizoma, Scutellariae Radix, and Magnetitum. It is administered orally in tablet form and is used to improve local microcirculation and auditory nerve function.

Brand names: Er Long Pian
Other names: Erlong Tablets耳聋片

Beyond the preview

Go deeper on Er Long Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Er Long Pian.

Explore the full profile